Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia

Four case reports and an in vitro combination synergy study

Nan Yao Lee, Chun Lung Wang, Yin Ching Chuang, Wen Liang Yu, Hsin Chun Lee, Chia Ming Chang, Li Rong Wang, Wen Chien Ko

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Infections caused by multidrug-resistant Acinetobacter baumannii have become a therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been successful in treating patients with these infections, these agents are not available on a worldwide basis. We describe four critically ill patients in Taiwan who were diagnosed with multidrug-resistant Acinetobacter baumannii bacteremia. All bacterial isolates from these patients were resistant to commonly available antibiotics, including carbapenems and sulbactam; however, combination therapy with a carbapenem and sulbactam led to favorable clinical outcomes in all four patients. We also conducted an in vitro study using isolates from these patients that showed that this drug combination had a synergistic effect with enhanced antibacterial activity against the isolates. Thus, a carbapenem-sulbactam combination may be a therapeutic alternative for multidrug-resistant Acinetobacter baumannii bacteremia in countries where colistin and tigecycline are not available for clinical use.

Original languageEnglish
Pages (from-to)1506-1511
Number of pages6
JournalPharmacotherapy
Volume27
Issue number11
DOIs
Publication statusPublished - Nov 2007
Externally publishedYes

Fingerprint

Sulbactam
Acinetobacter baumannii
Carbapenems
Bacteremia
Critical Illness
Colistin
Therapeutics
Drug Combinations
Infection
Taiwan
In Vitro Techniques

Keywords

  • Acinetobacter baumannii
  • Bacteremia
  • Carbapenem
  • Sulbactam

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia : Four case reports and an in vitro combination synergy study. / Lee, Nan Yao; Wang, Chun Lung; Chuang, Yin Ching; Yu, Wen Liang; Lee, Hsin Chun; Chang, Chia Ming; Wang, Li Rong; Ko, Wen Chien.

In: Pharmacotherapy, Vol. 27, No. 11, 11.2007, p. 1506-1511.

Research output: Contribution to journalArticle

Lee, Nan Yao ; Wang, Chun Lung ; Chuang, Yin Ching ; Yu, Wen Liang ; Lee, Hsin Chun ; Chang, Chia Ming ; Wang, Li Rong ; Ko, Wen Chien. / Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia : Four case reports and an in vitro combination synergy study. In: Pharmacotherapy. 2007 ; Vol. 27, No. 11. pp. 1506-1511.
@article{e896abb3cc2945e9983890fb36f922e2,
title = "Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: Four case reports and an in vitro combination synergy study",
abstract = "Infections caused by multidrug-resistant Acinetobacter baumannii have become a therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been successful in treating patients with these infections, these agents are not available on a worldwide basis. We describe four critically ill patients in Taiwan who were diagnosed with multidrug-resistant Acinetobacter baumannii bacteremia. All bacterial isolates from these patients were resistant to commonly available antibiotics, including carbapenems and sulbactam; however, combination therapy with a carbapenem and sulbactam led to favorable clinical outcomes in all four patients. We also conducted an in vitro study using isolates from these patients that showed that this drug combination had a synergistic effect with enhanced antibacterial activity against the isolates. Thus, a carbapenem-sulbactam combination may be a therapeutic alternative for multidrug-resistant Acinetobacter baumannii bacteremia in countries where colistin and tigecycline are not available for clinical use.",
keywords = "Acinetobacter baumannii, Bacteremia, Carbapenem, Sulbactam",
author = "Lee, {Nan Yao} and Wang, {Chun Lung} and Chuang, {Yin Ching} and Yu, {Wen Liang} and Lee, {Hsin Chun} and Chang, {Chia Ming} and Wang, {Li Rong} and Ko, {Wen Chien}",
year = "2007",
month = "11",
doi = "10.1592/phco.27.11.1506",
language = "English",
volume = "27",
pages = "1506--1511",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "11",

}

TY - JOUR

T1 - Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia

T2 - Four case reports and an in vitro combination synergy study

AU - Lee, Nan Yao

AU - Wang, Chun Lung

AU - Chuang, Yin Ching

AU - Yu, Wen Liang

AU - Lee, Hsin Chun

AU - Chang, Chia Ming

AU - Wang, Li Rong

AU - Ko, Wen Chien

PY - 2007/11

Y1 - 2007/11

N2 - Infections caused by multidrug-resistant Acinetobacter baumannii have become a therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been successful in treating patients with these infections, these agents are not available on a worldwide basis. We describe four critically ill patients in Taiwan who were diagnosed with multidrug-resistant Acinetobacter baumannii bacteremia. All bacterial isolates from these patients were resistant to commonly available antibiotics, including carbapenems and sulbactam; however, combination therapy with a carbapenem and sulbactam led to favorable clinical outcomes in all four patients. We also conducted an in vitro study using isolates from these patients that showed that this drug combination had a synergistic effect with enhanced antibacterial activity against the isolates. Thus, a carbapenem-sulbactam combination may be a therapeutic alternative for multidrug-resistant Acinetobacter baumannii bacteremia in countries where colistin and tigecycline are not available for clinical use.

AB - Infections caused by multidrug-resistant Acinetobacter baumannii have become a therapeutic challenge for clinicians worldwide. Although colistin and tigecycline have been successful in treating patients with these infections, these agents are not available on a worldwide basis. We describe four critically ill patients in Taiwan who were diagnosed with multidrug-resistant Acinetobacter baumannii bacteremia. All bacterial isolates from these patients were resistant to commonly available antibiotics, including carbapenems and sulbactam; however, combination therapy with a carbapenem and sulbactam led to favorable clinical outcomes in all four patients. We also conducted an in vitro study using isolates from these patients that showed that this drug combination had a synergistic effect with enhanced antibacterial activity against the isolates. Thus, a carbapenem-sulbactam combination may be a therapeutic alternative for multidrug-resistant Acinetobacter baumannii bacteremia in countries where colistin and tigecycline are not available for clinical use.

KW - Acinetobacter baumannii

KW - Bacteremia

KW - Carbapenem

KW - Sulbactam

UR - http://www.scopus.com/inward/record.url?scp=35848952749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848952749&partnerID=8YFLogxK

U2 - 10.1592/phco.27.11.1506

DO - 10.1592/phco.27.11.1506

M3 - Article

VL - 27

SP - 1506

EP - 1511

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 11

ER -